SCHEMBL26807466

SCHEMBL26807466

Cc1cccc(-c2cc(Oc3ccc(N4CCNCC4)cc3)nc(NS(=O)(=O)c3cnn(C)c3)n2)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 1/20 0.38
▸ RIPK2 O43353 6/20 0.37
▸ ACVR1 Q04771 6/20 0.37
▸ NOD2 Q9HC29 6/20 0.37
▸ HTR6 P50406 2/20 0.36
▸ GUSB P08236 5/20 0.35
▸ JAK3 P52333 2/20 0.35
▸ LCK P06239 1/20 0.35
▸ BTK Q06187 1/20 0.35
▸ TNK2 Q07912 1/20 0.35
▸ ALOX12 P18054 1/20 0.34
▸ MAPK10 P53779 1/20 0.34
▸ LTA4H P09960 1/20 0.34
▸ PTK2 Q05397 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ BRD2 P25440 1/20 0.33
▸ BRD3 Q15059 1/20 0.33
▸ BRDT Q58F21 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566726 0.94 RIPK2 (0.39) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL26807316 0.94 RIPK2 (0.39) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL24309665 0.92 GUSB (0.39) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL29566865 0.92 GUSB (0.39) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL24310583 0.91 RIPK2 (0.38) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL26809994 0.88 GUSB (0.36) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL26807468 0.88 GUSB (0.42) FLT3RIPK2ACVR1NOD2HTR6
SCHEMBL26807459 0.88 NOD2 (0.40) FLT3RIPK2ACVR1NOD2JAK3
SCHEMBL26807463 0.88 ACVR1 (0.40) RIPK2ACVR1NOD2HTR6GUSB
SCHEMBL26808355 0.87 HTR6 (0.39) FLT3RIPK2ACVR1NOD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B FLT3 4133/4885RIPK2 3698/4885ACVR1 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback